Gregory Taylor is an Infectious Disease physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
22 S Greene St
Baltimore, MD 212011544
Telephone
410-328-5725Registry record last updated 13 Aug 2010.
Clinical trials
- C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
Sponsor: UNC Lineberger Comprehensive Cancer Center
- ExPECT: Extraperitoneal End Colostomy Trial
Sponsor: Swansea Bay University Health Board
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
34.6%Statin13.4%Atorvastatin Calcium79%Rosuvastatin Calcium14%Pravastatin Sodium7%Part D<11 patientsCalcium channel blocker5.9%Amlodipine Besylate66%Nifedipine Er18%Amlodipine Besylate-Benazepril10%Amlodipine-Valsartan6%Part D<11 patients+ 9 more classes in this area
Anti-infectives
27.5%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor8.5%Triumeq61%Descovy24%Emtricitabine-Tenofovir Disop6%Abacavir5%Abacavir-Lamivudine4%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor8.1%Tivicay44%Juluca28%Dovato16%Isentress9%Tivicay Pd5%Part D<11 patients+ 7 more classes in this area
Nervous system
13.8%SSRI4.1%Escitalopram Oxalate34%Sertraline Hcl30%Trazodone Hcl17%Paroxetine Hcl10%Citalopram Hbr10%Part D<11 patientsGabapentinoids2.9%Gabapentin100%Part D≥20 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
- Baltimore CASCADE Study Site (BaCSS Project)
University of Maryland Baltimore
FY2025$733,995UG1CA284883 - Baltimore CASCADE Study Site (BaCSS Project)
University of Maryland Baltimore
FY2024$308,998UG1CA284883 - Baltimore CASCADE Study Site (BaCSS Project)
University of Maryland Baltimore
FY2023$308,998UG1CA284883
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”